These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 1346404)
61. How long should adjuvant tamoxifen be continued? Tripathy D Oncology (Williston Park); 1994 Oct; 8(10):25-33; discussion 33, 37-8. PubMed ID: 7803214 [TBL] [Abstract][Full Text] [Related]
62. Estrogen for the Treatment and Prevention of Breast Cancer: A Tale of 2 Karnofsky Lectures. Abderrahman B; Jordan VC Cancer J; 2022 May-Jun 01; 28(3):163-168. PubMed ID: 35594462 [TBL] [Abstract][Full Text] [Related]
63. Tamoxifen for the prevention of breast cancer in the high-risk woman. Morrow M; Jordan VC Ann Surg Oncol; 2000; 7(1):67-71. PubMed ID: 10674451 [No Abstract] [Full Text] [Related]
64. Long-term prophylactic use of tamoxifen: is it safe? Williams GM; Iatropoulos MJ; Hard GC Eur J Cancer Prev; 1992 Aug; 1(5):386-7. PubMed ID: 1463993 [No Abstract] [Full Text] [Related]
65. Tamoxifen and liver cancer. Hard GC; Williams GM; Iatropoulos MJ Lancet; 1993 Aug; 342(8868):444-5. PubMed ID: 8101953 [No Abstract] [Full Text] [Related]
66. Laboratory studies on the mode of action and application of antiestrogen for breast cancer therapy. Jordan VC Int J Biol Markers; 1988; 3(1):53-4. PubMed ID: 3074131 [No Abstract] [Full Text] [Related]
67. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity: a prospective study of 63 patients. Flach AJ Surv Ophthalmol; 1994; 38(4):392-3. PubMed ID: 8160114 [No Abstract] [Full Text] [Related]
68. "Intermediate" doses of tamoxifen in progressive advanced breast-cancer. Watkins SM Lancet; 1987 Dec; 2(8573):1457. PubMed ID: 2892010 [No Abstract] [Full Text] [Related]
69. Development of breast cancer during long-term tamoxifen therapy for lymphangioleiomyomatosis. Millward MJ; Cantwell BM Eur J Cancer; 1991; 27(6):806. PubMed ID: 1829929 [No Abstract] [Full Text] [Related]
71. Tamoxifen for carcinoma of the male breast. Coffman BL Ann Intern Med; 1993 May; 118(9):749. PubMed ID: 8460869 [No Abstract] [Full Text] [Related]
72. European tamoxifen studies moving ahead. Vanchieri C J Natl Cancer Inst; 1993 Sep; 85(18):1450-1. PubMed ID: 8360925 [No Abstract] [Full Text] [Related]
75. Troglitazone-Induced PRODH/POX-Dependent Apoptosis Occurs in the Absence of Estradiol or ERβ in ER-Negative Breast Cancer Cells. Lewoniewska S; Oscilowska I; Huynh TYL; Prokop I; Baszanowska W; Bielawska K; Palka J J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682765 [TBL] [Abstract][Full Text] [Related]
76. Transgenic rat models for mutagenesis and carcinogenesis. Nohmi T; Masumura K; Toyoda-Hokaiwado N Genes Environ; 2017; 39():11. PubMed ID: 28174618 [TBL] [Abstract][Full Text] [Related]
77. The effect of estrogen on prolidase-dependent regulation of HIF-1α expression in breast cancer cells. Surazynski A; Miltyk W; Prokop I; Palka J Mol Cell Biochem; 2013 Jul; 379(1-2):29-36. PubMed ID: 23549681 [TBL] [Abstract][Full Text] [Related]
78. Hormone-induced protection against breast cancer. Sivaraman L; Medina D J Mammary Gland Biol Neoplasia; 2002 Jan; 7(1):77-92. PubMed ID: 12160088 [TBL] [Abstract][Full Text] [Related]
79. Cdc25B functions as a novel coactivator for the steroid receptors. Ma ZQ; Liu Z; Ngan ES; Tsai SY Mol Cell Biol; 2001 Dec; 21(23):8056-67. PubMed ID: 11689696 [TBL] [Abstract][Full Text] [Related]